Firefly Neuroscience to Showcase AI-Powered Brain Health Solutions at October Investor Conferences
Curated by THEOUTPOST
On Sat, 12 Oct, 12:02 AM UTC
2 Sources
2 Sources
[1]
Firefly Neuroscience to Participate in Upcoming October Investor Conferences By Investing.com
TORONTO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (Firefly, we, or the Company) (NASDAQ: AIFF), an Artificial Intelligence (AI) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that management will participate in the following October 2024 investor conferences: To schedule a one-on-one investor meeting with Mr. Olsen, please contact your representatives at Maxim, ThinkEquity or email KCSA Strategic Communications at Firefly@KCSA.com. About Firefly Firefly (NASDAQ: AIFF) is an Artificial Intelligence (AI) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly's FDA-510(k) cleared Brain Network (LON:NETW) Analytics (BNAâ„¢) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNAâ„¢ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use. Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly's extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNAâ„¢, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician's ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient's outcome. Please visit https://fireflyneuro.com/ for more information.
[2]
Firefly Neuroscience to Participate in Upcoming October Investor Conferences - Firefly Neuroscience (NASDAQ:AIFF)
TORONTO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") AIFF, an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that management will participate in the following October 2024 investor conferences: Maxim Healthcare Virtual Summit Details: Date: October 15-17, 2024 Presentation Format: Fireside Chat with Maxim Analyst, Allen Klee Presentation Day and Time: Thursday, October 17th at 10:00 a.m. ET Webcast: https://investors.fireflyneuro.com/events-presentations ThinkEquity Conference Details: Date: October 30, 2024 Location: Mandarin Oriental Hotel, New York, NY Presentation Day and Time: Wednesday, October 30th at 11:00 a.m. ET Webcast: https://investors.fireflyneuro.com/events-presentations To schedule a one-on-one investor meeting with Mr. Olsen, please contact your representatives at Maxim, ThinkEquity or email KCSA Strategic Communications at Firefly@KCSA.com. About Firefly Firefly AIFF is an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly's FDA-510(k) cleared Brain Network Analytics (BNAâ„¢) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNAâ„¢ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use. Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly's extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNAâ„¢, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician's ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient's outcome. Please visit https://fireflyneuro.com/ for more information. Investor Contact KCSA Strategic Communications Valter Pinto or Jack Perkins (212) 896-1254 Firefly@KCSA.com Media Contact KCSA Strategic Communications Raquel Cona, Vice President (516) 779-2630 Rcona@KCSA.com Market News and Data brought to you by Benzinga APIs
Share
Share
Copy Link
Firefly Neuroscience, an AI company specializing in brain health diagnostics, announces its participation in two major investor conferences in October 2024, highlighting its innovative Brain Network Analytics technology.
Firefly Neuroscience Gears Up for October Investor Conferences
Firefly Neuroscience, Inc. (NASDAQ: AIFF), an innovative AI company focused on improving brain health outcomes, has announced its participation in two significant investor conferences this October. The company, which specializes in developing solutions for patients with neurological and mental disorders, aims to showcase its groundbreaking technology to potential investors and industry professionals 12.
Conference Details and Presentation Formats
The company will be participating in two distinct events:
-
Maxim Healthcare Virtual Summit (October 15-17, 2024):
- Format: Fireside Chat with Maxim Analyst, Allen Klee
- Date and Time: Thursday, October 17th at 10:00 a.m. ET
- Webcast available on Firefly's investor relations website
-
ThinkEquity Conference (October 30, 2024):
- Location: Mandarin Oriental Hotel, New York, NY
- Presentation: Wednesday, October 30th at 11:00 a.m. ET
- Webcast also available on the company's investor relations site
Investors interested in one-on-one meetings with Firefly's management can arrange them through their Maxim or ThinkEquity representatives, or by contacting KCSA Strategic Communications 2.
Firefly's Innovative AI-Powered Technology
At the heart of Firefly's offerings is its FDA-510(k) cleared Brain Network Analytics (BNAâ„¢) technology. This AI-driven solution is revolutionizing the diagnosis and treatment monitoring of various neurological and mental health conditions, including depression, dementia, anxiety disorders, concussions, and ADHD 1.
The BNAâ„¢ technology leverages artificial intelligence and machine learning, drawing insights from Firefly's extensive proprietary database. This database comprises standardized, high-definition longitudinal electroencephalograms (EEGs) from over 17,000 patients, representing twelve different disorders as well as clinically normal patients 2.
Commercial Launch and Target Markets
Firefly is currently in the process of launching BNAâ„¢ commercially. The company is targeting two primary markets:
- Pharmaceutical companies engaged in drug research and clinical trials
- Medical practitioners for clinical use
When used in conjunction with an FDA-cleared EEG system, BNAâ„¢ provides clinicians with comprehensive insights into brain function. These insights can significantly enhance a clinician's ability to accurately diagnose mental and cognitive disorders and determine the most suitable therapy or drug to optimize patient outcomes 12.
Firefly's Market Position and Future Prospects
As an AI company in the healthcare sector, Firefly Neuroscience is positioning itself at the intersection of technology and brain health. With its FDA clearance, patent protection, and a database built over 15 years, the company appears to be well-positioned to capitalize on the growing demand for innovative mental health solutions 1.
The upcoming investor conferences present a significant opportunity for Firefly to showcase its technology and business model to potential investors and partners. As the company moves forward with its commercial launch, these events could play a crucial role in securing additional funding and partnerships to fuel its growth and market expansion 2.
Firefly Neuroscience to Showcase AI-Powered Brain Health Solutions at Florida Capital Event
Firefly Neuroscience, an AI company developing innovative brain health solutions, announces its participation in the 8th Annual Florida Capital Event. The company's FDA-cleared Brain Network Analytics technology aims to revolutionize diagnostics and treatment monitoring for neurological and mental disorders.
2 Sources
2 Sources
Firefly Neuroscience Secures $12.4 Million Financing to Advance AI-Powered Brain Health Technology
Firefly Neuroscience, an AI company focused on brain health solutions, has closed a financing deal of up to $12.4 million to support the commercialization of its FDA-cleared Brain Network Analytics technology.
2 Sources
2 Sources
Firefly Neuroscience's AI-Powered EEG Analytics Show Promise in Drug Development and Neuropsychiatric Care
Firefly Neuroscience's FDA-cleared BNAâ„¢ platform, utilizing AI and machine learning, demonstrates significant potential in providing objective measures for drug efficacy and cognitive changes in neuropharmacology and psychiatry.
2 Sources
2 Sources
Firefly Neuroscience Grants Inducement Shares to Executive Chairman, Highlighting AI-Driven Brain Health Solutions
Firefly Neuroscience, an AI company focused on brain health, announces an inducement grant to its Executive Chairman and discusses its innovative Brain Network Analytics technology.
2 Sources
2 Sources
Firefly Neuroscience Unveils AI-Powered Brain Age Biomarker Using FDA-Cleared BNAâ„¢ Platform
Firefly Neuroscience announces a breakthrough in assessing cognitive brain age using its FDA-cleared BNAâ„¢ technology, potentially revolutionizing early detection and monitoring of neurological disorders like Alzheimer's.
2 Sources
2 Sources
Your one-stop AI hub
The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.
The Outpost
Keep in touch
© 2025 TheOutpost.AI All rights reserved